M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpaceOf the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.OncologyRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. Oncology Read full story Post navigation Previous: Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billionNext: Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026